{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-257400","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2026-06-04T20:10:06+00:00","discovered_at":"2026-06-04T20:11:00.255562+00:00","generated_at":"2026-06-04T20:41:44.303798+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Tenax Therapeutics reports results of 2026 annual shareholder meeting","bullets":["Stockholders elected seven directors: June Almenoff (17.36M for), Michael Davidson (15.76M), Declan Doogan, Christopher T. Giordano, Robyn M. Hunter, Gerald T. Proehl, Stuart Rich.","Auditor Cherry Bekaert LLP ratified with 21.30M for, 3,688 against, 11,073 abstain, no broker non-votes.","All director nominees received over 17.3 million votes in favor except Michael Davidson with 15.76 million.","The meeting was held on June 2, 2026; results filed June 4, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-257400","json":"https://secwatch.observer/filing/0001193125-26-257400.json","markdown":"https://secwatch.observer/filing/0001193125-26-257400.md","text":"https://secwatch.observer/filing/0001193125-26-257400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000119312526257400/0001193125-26-257400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000119312526257400/d69762d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T20:41:44.303798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae5bc231b923ef93d4090323c7033cbbde84b50f","claim":"TENAX THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Cherry Bekaert LLP as Independent Registered Public Accounting Firm at the 2026-06-02 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 by the votes indicated below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526257400/0001193125-26-257400-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"},{"claim_id":"b0fd9124f7fa3302cd6cfd10b737dc530ccd0865","claim":"TENAX THERAPEUTICS, INC. shareholders approved Election of Directors at the 2026-06-02 meeting.","evidence_excerpt":"The Company’s stockholders elected each of the following individuals to the Company’s Board of Directors for a one-year term expiring in 2027, or until his or her successor is duly elected and qualified, by the votes indicated below.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526257400/0001193125-26-257400-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-02"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}